Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Sygdomsmekanismer og nye behandlingsmetoder ved migræne

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{76ba6874c0704740b797650609f76811,
title = "Sygdomsmekanismer og nye behandlingsmetoder ved migr{\ae}ne",
abstract = "Migraine is the most prevalent disabling neurological disorder. The management of patients with migraine has been hampered by lack of effective and well-tolerated acute and preventive therapies. Based on improved insights into the basic mechanisms of migraine, new and targeted treatments are currently undergoing large-scale testing. Among the most promising agents for migraine prevention are humanized antibodies against calcitonin gene-related peptide (CGRP) or the CGRP receptor. If proven effective, these new treatments may emerge to improve the lives of millions of individuals worldwide disabled by migraine.",
author = "Hansen, {Jakob M{\o}ller} and Messoud Ashina",
year = "2016",
month = dec,
day = "19",
language = "Dansk",
volume = "178",
pages = "V07160507",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "51",

}

RIS

TY - JOUR

T1 - Sygdomsmekanismer og nye behandlingsmetoder ved migræne

AU - Hansen, Jakob Møller

AU - Ashina, Messoud

PY - 2016/12/19

Y1 - 2016/12/19

N2 - Migraine is the most prevalent disabling neurological disorder. The management of patients with migraine has been hampered by lack of effective and well-tolerated acute and preventive therapies. Based on improved insights into the basic mechanisms of migraine, new and targeted treatments are currently undergoing large-scale testing. Among the most promising agents for migraine prevention are humanized antibodies against calcitonin gene-related peptide (CGRP) or the CGRP receptor. If proven effective, these new treatments may emerge to improve the lives of millions of individuals worldwide disabled by migraine.

AB - Migraine is the most prevalent disabling neurological disorder. The management of patients with migraine has been hampered by lack of effective and well-tolerated acute and preventive therapies. Based on improved insights into the basic mechanisms of migraine, new and targeted treatments are currently undergoing large-scale testing. Among the most promising agents for migraine prevention are humanized antibodies against calcitonin gene-related peptide (CGRP) or the CGRP receptor. If proven effective, these new treatments may emerge to improve the lives of millions of individuals worldwide disabled by migraine.

M3 - Tidsskriftartikel

C2 - 28041540

VL - 178

SP - V07160507

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 51

ER -

ID: 49696350